Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Royalty Pharma Pays $3.3B for Cystic Fibrosis Royalties

By Drug Discovery Trends Editor | November 19, 2014

Royalty Pharma announced its acquisition of royalties on Vertex Pharmaceuticals’ cystic fibrosis treatments owned by Cystic Fibrosis Foundation Therapeutics’ (“CFFT”), an affiliate of the Cystic Fibrosis Foundation, for a cash payment of $3.3 billion.
 
“We are honored to work with the Cystic Fibrosis Foundation on this extraordinary royalty transaction,” said Pablo Legorreta, Royalty Pharma’s Founder & Chief Executive Officer.  “Our goal is to be the premier provider of innovative capital to enable the life sciences industry to accelerate development of important novel therapies.  Furthermore, this transaction represents an important validation of the Foundation’s bold vision under Dr. Beall’s leadership to fund new drug development as part of its successful venture philanthropy model.  These therapies are notable examples of fundamental research leading to breakthrough treatments that dramatically improve patient’s lives.”
 
“This is a transformational moment for people with cystic fibrosis and the entire CF community,” said Robert J. Beall, Ph.D., President and Chief Executive Officer of the Cystic Fibrosis Foundation.  “These new funds give us a tremendous opportunity to supercharge our efforts to develop lifesaving new therapies, ensure that the best possible care and resources are available for people with CF, and pursue daring, new opportunities that one day may lead to a permanent, lifelong cure for this disease.”
 
Cystic fibrosis is a fatal genetic disease that primarily affects the lungs and digestive system.  An estimated 70,000 children and adults worldwide have cystic fibrosis.  For most of the last century, scientists and physicians had very little understanding of the disease, other than the fact that very few patients ever reached adulthood.  In 1989, CFF-sponsored scientists identified the cystic fibrosis transmembrane conductance regulator (the “CFTR”) gene, which is defective in patients with cystic fibrosis.  This breakthrough 25 years ago paved the way for the discovery of Kalydeco® and other products, which were specifically engineered to treat the underlying cause of cystic fibrosis. 
 
Bank of America Merrill Lynch acted as financial advisors to Royalty Pharma in this transaction and Goodwin Procter acted as legal advisor.  Royalty Pharma financed this acquisition with cash on hand and a $2.7 billion unsecured term loan provided by Bank of America Merrill Lynch.  Morgan Stanley acted as the exclusive Structuring Agent for CFFT and Shaner & Lubitz acted as legal counsel.
 
Source: Royalty Pharma

Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE